Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid (October 2021)
07 October, Athens, Greece. Health systems have been severely jolted by COVID-19, causing widespread disruption to the provision of health care worldwide. As countries shift to investment in healthcare system recovery and ongoing management of COVID-19, off-patent medicines will be critical to their success.
Annual Conference Opening Remarks Suzette Kox (October 2021)
It is my great pleasure and honor to welcome you all to the Joint Annual Conference of Medicines for Europe and IGBA here in Athens under the title Goal 2030: Access For All...
More Articles...
- Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19 pandemic response (July 2021)
- IGBA Launches a Whitepaper: a Vision for the Global Generic and Biosimilar Medicines Industry (July 2021)
- IGBA Applauds UK MHRA Biosimilar Guidance Revision: Science-driven Evolution for Sustainable Access to Biologics (May 2021)
- The WHO Global Diabetes Compact: an opportunity for lasting change (April 2021)